Top 5 layoffs of 2007
2007 has been a rough year for a number of the pharmaceutical and biotech industry’s biggest players. Concerns about patent expirations, falling sales due to drug safety concerns, redundancy from acquisitions and a general need streamline operations contributed to these companies’ decisions to cut employees. Check out this list of the top five pharma and biotech layoffs of 2007 for more on the cuts and a look at what these companies are doing to turn things around.
4. Johnson & Johnson - 5,000 jobs
5. GlaxoSmithKline - 5,000 jobs*
6. Bristol-Myers Squibb - 4,800 jobs*
*These job cut announcement occured after the date this report was originally published. GSK announced cuts on 10/25/07, BMS on 12/6/07 and Novartis on 12/13/07.
Comments
It would be helpful to see the cuts against the total number of employees and to note if the cuts are worldwide or just US based. I ask for that since we are outsourcing everything out to China or India.
Outsouring to India and China never happens in the R&D department, it only usually manufacturing to cut costs! SO one cant blame layoffs just on outsourcing !!
You left out Merck & Co. They are very cautious about thr public knowing tehy are eliminating positions/restructuring, but 2007 will leave thousands of victims with no jobs
What pharma plants have been annouced for closure?
"Outsouring to India and China never happens in the R&D department..." Ah, dude. Get a clue. It's happened and happening as we speak.
what about Lilly...they had closed a plant in Lafayette,IN that manufactured chemo...used to laugh at the locals working at the plant say "the product was used for care and compassion"...lol
Any announcement from Virtualscopics in Rochester NY on the reduction of their workforce? I heard that they cut 10% of their employees.
To the people trying to imply that allowing a free global labor market is responsible for layoffs (ie, implying we should all run out and elect as many democrats as you can because they are against free trade), consider that the now expanding economies in countries like China and India are beginning to show a significant improvement in demand for US products - particularly pharmaceuticals. Because their economies are improving from our outsourcing labor, more pressure is placed on their governments to cut back on unlawful generics, and as a result new demand from these countries may actually be what SAVES the pharmaceutical industry in the coming years. If that is too complicated for some to understand, consider this. No matter how many people will use a marketed drug, the cost of developing it remains constant. The more consumers, the better the profit margins. By bolstering the economies of India and China, we have just added 2 billion more consumers to the market who can now share the cost of developing new drugs. Tell me again how bad outsourcing is....
Amen. Someone finally talking sense on this board!
too bad that doesn't stop teva from ripping off protonix and the chinese from wholesale ripoff of epo, as well as viagra.
it is wishful thinking to assume that when these economies can afford these drugs, that they'll be buying from an arcane, in debt-ridden countries, full of over regulated industry such as american pharma.
instead they'll be making their own using the same technology we handed them on a silver platter when we sold our futures for a box of cheap plastic choo-choos and tainted heparin.
how bad is outsourcing? every major pharma has a site setup in china. every major pharma is doing some type of low level discovery research in china or india or both and every pharma dreams of outsourcing your job for $7 an hour. think you're special? wrong again.
ITs not the outsourcing phenomena, its the drying up of R&D pipelines. Tell me 2 drugs launched in the last 5 years that are blockbusters (> $ 1 billion in sales annually). They would be no longer the BIG PHARMA, but they need to re-invent themselves as companies that care for people.
Does anyone know if any of these layoffs affected Pharmaceutical Sales reps? Or is it more R&D and production related?
I agree with the comment: "It would be helpful to see the cuts against the total number of employees and to note if the cuts are worldwide or just US based". Also, these companies have probably added positions as well which would offset the numbers somewhat.
Then there are other companies out there that will buy up, or at least attempt to buy up their competitors, to get their technologies and product. The thing with that is that once the honeymoon period is over with and they've gotten what they want, they will shut you down. I'm going through something like that right now with my corporate raider employers.
Post new comment
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight

